Loading…
← CockpitCompetitor Analysis › CHE Chemed CorporationOpen in the cockpit ↗

Chemed CorporationCHECompetitor analysis, valuation and peers

United States · USD·Health Care›Hospital/Nursing Management

Unusual conglomerate combining VITAS Healthcare hospice care with Roto-Rooter plumbing and drain-cleaning services.

Momentum strong 79
Mkt cap
$7.12B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$89.0M
20-day average traded
Fwd P/E
20.2×
forward earnings
ROIC−WACC
+16.7 pp
WACC 7.4%
Hurdle
-1 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$546.72
1D0.0%
1W-0.7%
1M+5.9%
3M+2.2%
6M+23.8%
YTD+27.8%
1Y+26.4%
ATR %2.5%
Beta0.10
52w lowhigh2.8% off high

What Chemed does

Unusual conglomerate combining VITAS Healthcare hospice care with Roto-Rooter plumbing and drain-cleaning services.

Is paid by Medicare, mostly under a fixed daily rate per hospice patient, so VITAS's income follows patient days and government payment rules. Roto-Rooter is paid directly by homeowners and businesses per job, through company-owned branches and franchisees. The two businesses are unrelated, and VITAS is the larger.

Products and services

  • Hospice care (VITAS Healthcare)
  • Plumbing & drain cleaning (Roto-Rooter)

Customers

  • Terminally ill patients & families (VITAS)
  • Homeowners & businesses needing plumbing service (

Where it sits in the supply chain

  • Healthcare services & consumer services
  • Hospice care (VITAS)
  • Plumbing/drain services (Roto-Rooter)

What could go right

  • Aging population hospice demand
  • Roto-Rooter service call volume growth

What could go wrong

  • Medicare hospice reimbursement/regulatory risk
  • Labor availability for service technicians

Moat: narrow (brand, scale, installed base). Leading hospice provider scale and the dominant national plumbing-service brand, an unusual but durable combo.

Headquarters: Cincinnati, Ohio, US · Founded: 1970 · Employees: 15,811

Named competitors

Chemed at a glance

Size Chemed (CHE) is a United States Health Care company (Hospital/Nursing Management) with a market value of $7.12B, the 953rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $546.72 on 18 Nov 2026.

Performance Over six months the shares gained 23.8%, against +2.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 18 in its peer set.

Growth Revenue grew 5.2% over the last twelve months (peer median +13.1%); the operating margin is 14.0% (peer median 12.4%).

Valuation It trades at 20.2× forward earnings against a peer median of 48.5× (6th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.7 points above its cost of capital (7.4% WACC).

Short interest Short interest is 6.1% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026CHE 124Peer median 103
Six months, rebased to 100: Chemed against the median of its 18 peers (local-currency closes).

Chemed financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.66B$2.53B$2.43B$2.26B$2.13B
Revenue growth—+4%+7%+6%—
Gross profit$825M$758M$791M$738M$706M
EBITDA$441M$406M$436M$404M$406M
Net income$282M$265M$302M$273M$250M
Free cash flow$295M$325M$368M$273M$253M
Capital expenditure$67.7M$62.8M$49.5M$56.9M$57.3M
Total debt$410M$155M$141M$155M$247M

Quarterly statements and history in the cockpit →

Chemed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+50%PACSASTERDMFORTISRHCMAXHEALTHUHSNHMEDANTASGRYNHCTHCBKDARDTEXECHE6-month return →1-month return →
Up and to the right = strong over both horizons. Chemed is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×PACSASTERDMFORTISRHCMANIPALHOSUHSNHMEDANTASGRYKIMSBKDARDTEXECHERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chemed is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%PACSASTERDMFORTISRHCMANIPALHOSMAXHEALTHUHSNHAPOLLOHOSPSGRYNHCTHCBKDCHEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chemed is the large dot.

Chemed competitors and peer comparison

Head to head with its named competitors (CHE vs EHC vs ADUS vs PNTG)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Chemed CHE$7.12B+24%+5%14%20.2×3.3%
Encompass Health EHC$13.2B+27%+9%18%20.1×5.7%
Addus HomeCare ADUS$2.25B+29%+12%11%16.2×4.0%
Pennant PNTG$1.26B+1%+39%6%23.7×20.7%

How Chemed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chemed against its 18 peers (data as of 18 Nov 2026)
MeasureCHEPeer medianRank in peer set
1-month return+5.9%+8.1%8th lowest of 19
6-month return+23.8%+2.4%6th highest of 18
Distance from 52-week high-2.8%-14.6%3rd highest of 19
Revenue growth (TTM)+5.2%+13.1%5th lowest of 19
Operating margin14.0%12.4%8th highest of 19
Forward P/E20.2×48.5×6th cheapest of 18
Growth the price implies (Req g, 7 yrs)3.3%14.8%4th least demanding of 17
Growth delivered (Del g)+4.0%+9.2%4th lowest of 17
Hurdle (Req g minus delivered)-0.7 pp+4.8 pp6th least demanding of 17
ROIC minus cost of capital+16.7 pp-1.2 pphighest of 19
EV / EBITDA17.0×21.6×8th cheapest of 17
Net debt / EBITDA0.8×2.3×2nd least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Chemed CHEUnited States$7.12B+24%+5%14%20.2×3.3%+4.0%
PACS PACSUnited States$7.35B+25%+11%8%17.5×7.5%+29.7%
Aster DM Quality Care ASTERDM.NSIndia$6.83B-2%+50%16%63.5×48.6%-11.6%
Fortis Healthcare FORTIS.NSIndia$6.40B-17%+18%17%48.5×42.5%+17.9%
Ramsay Health Care RHC.AXAustralia$8.31B+41%+4%5%31.4×14.0%+8.3%
Manipal Health Enterprises MANIPALHOS.NSIndia$9.69Bn/a+25%19%66.5×32.9%+28.8%
Max Healthcare Institute MAXHEALTH.NSIndia$10.6B-4%+15%21%55.2×45.3%+27.2%
Universal Health Services UHSUnited States$10.7B+13%+8%11%8.3×-1.8%+8.5%
Narayana Hrudayalaya NH.NSIndia$4.13B0%+71%13%34.2×31.2%+25.0%
Global Health MEDANTA.NSIndia$4.13B+16%+26%17%50.4×n/an/a
Apollo Hospitals Enterprise APOLLOHOSP.NSIndia$13.6B+10%+19%12%51.0×33.3%+19.0%
Surgery Partners SGRYUnited States$3.53B+100%+2%13%77.2×15.6%+12.2%
Krishna Institute of Medical Sciences KIMS.NSIndia$3.41B+2%+35%11%81.9×n/an/a
National HealthCare NHCUnited States$3.16B+1%+6%0%n/a6.4%+9.7%
Tenet Healthcare THCUnited States$21.6B+45%+6%17%13.4×-1.4%+3.9%
Topchoice Medical 600763.SSChina$2.33B-12%+7%26%24.8×12.4%+6.9%
Brookdale Senior Living BKDUnited States$2.06B-36%-8%6%482.6×19.3%-1.4%
Ardent Health ARDTUnited States$2.03B+52%+2%5%11.9×-1.7%+8.7%
Extendicare EXE.TOCanada$1.91B-16%+36%9%19.3×10.8%+8.5%

Questions

Who are Chemed's main competitors?
Named competitors: Amedisys (private or unlisted), Chemed's Roto-Rooter vs local plumbers (private or unlisted), Encompass Health (EHC), Enhabit (private or unlisted), Addus HomeCare (ADUS), Pennant Group (PNTG). The cockpit's measured peer set (industry) also includes PACS (PACS), Aster DM Quality Care (ASTERDM.NS), Fortis Healthcare (FORTIS.NS), Ramsay Health Care (RHC.AX), Manipal Health Enterprises (MANIPALHOS.NS), Max Healthcare Institute (MAXHEALTH.NS).
Is Chemed expensive compared with its peers?
On forward p/e it trades at 20.2× against a peer median of 48.5×, 6th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Chemed stock performed?
Over six months to 18 Nov 2026 the shares returned +23.8% against +2.4% for the median peer; over one year +26.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.